Carolina S. Ilkow

Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma.

Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.

Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.

Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses.

Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis.

Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization.

Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment.

Personalized oncology and BRAF melanoma: model development, drug discovery, and clinical correlation.

Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.

Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.

SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition.

A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion.

Oncolytic Virus Immunotherapy.